Literature DB >> 26432767

The Impact of Uninterrupted Warfarin on Hand and Wrist Surgery.

Ljiljana Bogunovic1, Richard H Gelberman1, Charles A Goldfarb1, Martin I Boyer1, Ryan P Calfee2.   

Abstract

PURPOSE: To determine the impact of uninterrupted use of warfarin on hand and wrist surgery.
METHODS: This single-center, prospective cohort trial enrolled adult patients undergoing hand and wrist surgery. Between May 2009 and August 2014, 47 surgical patients receiving uninterrupted warfarin (50 procedures) were enrolled and matched as a group by age and procedure type to 48 surgical patients (50 procedures) who were not prescribed warfarin. Complications, defined as bleeding, infection, or wound dehiscence requiring reoperation, were recorded for each group. Surgical outcome measures were composed of objective findings affected by surgical site bleeding (ie, ecchymosis extent, hematoma presence, 2-point discrimination) and standardized patient-rated assessments (Quick-Disabilities of the Arm, Shoulder, and Hand, and visual analog scales: pain and swelling). We collected data preoperatively and at 2 and 4 weeks postoperatively. Statistical analyses contrasted complications and outcomes data between patient groups.
RESULTS: One procedure (2%; 95% confidence interval, 0% to 11%) in a patient taking warfarin was complicated by hematoma requiring reoperation resulting from an elevated postoperative international normalized ratio of 5.4. There were no complications among controls (0%; 95% confidence interval, 0% to 7%). At 2 weeks postoperatively, patients receiving warfarin more frequently had hematomas (28% vs 10%) and demonstrated a greater extent of ecchymosis from the surgical incision (50 vs 19 mm). At 4 weeks, no differences existed in hematoma presence or extent of ecchymosis between groups. The incidence of transiently elevated 2-point discrimination was not different between groups (10% warfarin; 6% controls). Visual analog scores for pain and swelling were not significantly different between groups at any time. Differences in Quick-Disabilities of the Arm, Shoulder, and Hand scores between groups did not exceed a minimal clinically important difference.
CONCLUSIONS: Uninterrupted use of warfarin in patients undergoing surgery of the hand and wrist was associated with an infrequent risk of bleeding complication requiring reoperation. Increased rates of hematoma and ecchymosis in patients taking warfarin normalized by 4 weeks postoperatively. TYPE OF STUDY/LEVEL OF EVIDENCE: Therapeutic II.
Copyright © 2015 American Society for Surgery of the Hand. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Anticoagulation; hand; surgery; warfarin; wrist

Mesh:

Substances:

Year:  2015        PMID: 26432767      PMCID: PMC4720967          DOI: 10.1016/j.jhsa.2015.07.037

Source DB:  PubMed          Journal:  J Hand Surg Am        ISSN: 0363-5023            Impact factor:   2.230


  24 in total

1.  Warfarin therapy and cataract surgery.

Authors:  A Morris; M J Elder
Journal:  Clin Exp Ophthalmol       Date:  2000-12       Impact factor: 4.207

2.  Anticoagulants and cataract surgery.

Authors:  D L Hall; W H Steen; J W Drummond; W A Byrd
Journal:  Ophthalmic Surg       Date:  1988-03

Review 3.  Perioperative management of patients receiving oral anticoagulants: a systematic review.

Authors:  Andrew S Dunn; Alexander G G Turpie
Journal:  Arch Intern Med       Date:  2003-04-28

4.  Outcomes of temporary interruption of rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: results from the rivaroxaban once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation (ROCKET AF).

Authors:  Matthew W Sherwood; James D Douketis; Manesh R Patel; Jonathan P Piccini; Anne S Hellkamp; Yuliya Lokhnygina; Alex C Spyropoulos; Graeme J Hankey; Daniel E Singer; Christopher C Nessel; Kenneth W Mahaffey; Keith A A Fox; Robert M Califf; Richard C Becker
Journal:  Circulation       Date:  2014-02-19       Impact factor: 29.690

Review 5.  When patients on warfarin need surgery.

Authors:  Amir K Jaffer; Daniel J Brotman; Nkem Chukwumerije
Journal:  Cleve Clin J Med       Date:  2003-11       Impact factor: 2.321

6.  Hypercoagulable state and thromboembolism following warfarin withdrawal in post-myocardial-infarction patients.

Authors:  L Grip; M Blombäck; S Schulman
Journal:  Eur Heart J       Date:  1991-11       Impact factor: 29.983

7.  Minimal clinically important differences of 3 patient-rated outcomes instruments.

Authors:  Amelia A Sorensen; Daniel Howard; Wen Hui Tan; Jeffrey Ketchersid; Ryan P Calfee
Journal:  J Hand Surg Am       Date:  2013-03-06       Impact factor: 2.230

8.  Stopping warfarin therapy is unnecessary for hand surgery.

Authors:  D L Wallace; M D Latimer; H J C R Belcher
Journal:  J Hand Surg Br       Date:  2004-06

9.  Elective hand surgery in patients taking warfarin.

Authors:  A Smit; G Hooper
Journal:  J Hand Surg Br       Date:  2004-06

10.  Outcomes of discontinuing rivaroxaban compared with warfarin in patients with nonvalvular atrial fibrillation: analysis from the ROCKET AF trial (Rivaroxaban Once-Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation).

Authors:  Manesh R Patel; Anne S Hellkamp; Yuliya Lokhnygina; Jonathan P Piccini; Zhongxin Zhang; Surya Mohanty; Daniel E Singer; Werner Hacke; Günter Breithardt; Jonathan L Halperin; Graeme J Hankey; Richard C Becker; Christopher C Nessel; Scott D Berkowitz; Robert M Califf; Keith A A Fox; Kenneth W Mahaffey
Journal:  J Am Coll Cardiol       Date:  2013-02-12       Impact factor: 24.094

View more
  1 in total

Review 1.  Hand and wrist surgery without suspending warfarin or oral antiplatelet - systematic review.

Authors:  Trajano Sardenberg; Francisco Simões Deienno; Raffaello de Freitas Miranda; Denis Varanda; Andréa Christina Cortopassi; Paulo Roberto de Almeida Silvares
Journal:  Rev Bras Ortop       Date:  2017-07-14
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.